CN107108527B - 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂 - Google Patents

共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂 Download PDF

Info

Publication number
CN107108527B
CN107108527B CN201580067182.7A CN201580067182A CN107108527B CN 107108527 B CN107108527 B CN 107108527B CN 201580067182 A CN201580067182 A CN 201580067182A CN 107108527 B CN107108527 B CN 107108527B
Authority
CN
China
Prior art keywords
macrocyclic compound
formula
alkyl
atoms
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580067182.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108527A (zh
Inventor
H·J·布雷斯林
O·吉拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atrin Pharmaceuticals LLC
Original Assignee
Atrin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrin Pharmaceuticals LLC filed Critical Atrin Pharmaceuticals LLC
Publication of CN107108527A publication Critical patent/CN107108527A/zh
Application granted granted Critical
Publication of CN107108527B publication Critical patent/CN107108527B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
CN201580067182.7A 2014-10-13 2015-10-13 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂 Active CN107108527B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462063176P 2014-10-13 2014-10-13
US62/063,176 2014-10-13
US201562104274P 2015-01-16 2015-01-16
US62/104,274 2015-01-16
PCT/US2015/055317 WO2016061097A1 (en) 2014-10-13 2015-10-13 Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN107108527A CN107108527A (zh) 2017-08-29
CN107108527B true CN107108527B (zh) 2022-08-02

Family

ID=55654998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580067182.7A Active CN107108527B (zh) 2014-10-13 2015-10-13 共济失调性毛细血管扩张和Rad3相关的(ATR)蛋白激酶抑制剂

Country Status (12)

Country Link
US (3) US9663535B2 (cg-RX-API-DMAC10.html)
EP (1) EP3207031B1 (cg-RX-API-DMAC10.html)
JP (1) JP6678679B2 (cg-RX-API-DMAC10.html)
KR (1) KR102569226B1 (cg-RX-API-DMAC10.html)
CN (1) CN107108527B (cg-RX-API-DMAC10.html)
AU (1) AU2015333738B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017007708B8 (cg-RX-API-DMAC10.html)
CA (1) CA2963973C (cg-RX-API-DMAC10.html)
ES (1) ES2879441T3 (cg-RX-API-DMAC10.html)
IL (1) IL251595B (cg-RX-API-DMAC10.html)
MX (1) MX389198B (cg-RX-API-DMAC10.html)
WO (1) WO2016061097A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HRP20240368T1 (hr) 2017-07-13 2024-08-30 Board Of Regents, The University Of Texas System Heterociklički inhibitori atr kinaze
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
US11267809B2 (en) 2017-09-14 2022-03-08 The Board Of Trustees Of The Leland Stanford Junior University BAF complex modulating compounds and methods of using the same
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CN110357905B (zh) * 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
WO2020014524A1 (en) 2018-07-12 2020-01-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
CN110950890B (zh) * 2018-09-27 2022-07-01 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2023201320A1 (en) 2022-04-14 2023-10-19 Atrin Pharmaceuticals LLC Atr inhibitors
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
WO2026064575A1 (en) 2024-09-19 2026-03-26 Aprea Therapeutics, Inc. Methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252961A1 (en) * 2012-03-06 2013-09-26 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
PL3354650T3 (pl) * 2008-12-19 2022-06-13 Vertex Pharmaceuticals Incorporated Związki przydatne jako inhibitory kinazy atr
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012125603A1 (en) * 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
EP2836485B1 (en) * 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252961A1 (en) * 2012-03-06 2013-09-26 Pfizer Inc. Macrocyclic derivatives for the treatment of diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物

Also Published As

Publication number Publication date
MX2017004515A (es) 2017-10-31
BR112017007708B8 (pt) 2023-10-24
EP3207031A1 (en) 2017-08-23
IL251595A0 (en) 2017-06-29
US9663535B2 (en) 2017-05-30
JP6678679B2 (ja) 2020-04-08
ES2879441T3 (es) 2021-11-22
BR112017007708A2 (pt) 2017-12-19
MX389198B (es) 2025-03-20
CA2963973C (en) 2023-01-10
EP3207031A4 (en) 2018-02-14
BR112017007708A8 (cg-RX-API-DMAC10.html) 2017-12-19
BR112017007708B1 (pt) 2023-07-25
US10196405B2 (en) 2019-02-05
AU2015333738B2 (en) 2020-03-26
KR20170082532A (ko) 2017-07-14
WO2016061097A1 (en) 2016-04-21
KR102569226B1 (ko) 2023-08-22
EP3207031B1 (en) 2021-04-14
AU2015333738A1 (en) 2017-05-04
CN107108527A (zh) 2017-08-29
IL251595B (en) 2022-04-01
JP2017531041A (ja) 2017-10-19
US20170226130A1 (en) 2017-08-10
CA2963973A1 (en) 2016-04-21
US9981989B2 (en) 2018-05-29
US20160102104A1 (en) 2016-04-14
US20180230168A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
US10196405B2 (en) Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
JP7339997B2 (ja) ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
WO2018157856A1 (zh) 酰胺类衍生物抑制剂及其制备方法和应用
AU2025202495A1 (en) Tricyclic PARP1 inhibitors and uses thereof
WO2014151936A9 (en) Octahydropyrrolopyrroles, their preparation and use
CN106349228B (zh) 取代的喹唑啉酮类化合物及其制备方法和用途
WO2022089389A1 (zh) 杂环化合物及其制备方法、药物组合物和应用
WO2023025225A1 (zh) 细胞周期蛋白k降解剂
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
CN105085436B (zh) 磺酰胺类衍生物及其在药物上的应用
WO2017180723A1 (en) Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
WO2023207447A1 (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
HK1235837B (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
HK1235837A1 (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
WO2025185734A1 (zh) 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
TW202408509A (zh) 雜芳基衍生物的藥物組合物及其在醫藥上的應用
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
HK40125804A (en) Compositions and methods for treating cancer
HK40121538A (en) Compositions and methods for treating cancer
TW202320767A (zh) 雜芳基衍生物parp抑制劑及其用途
HK40077297B (en) Aza-quinoline compounds and uses thereof
HK40037519B (en) Substituted heterocyclic inhibitors of ptpn11
HK40034342B (en) Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1235837

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant